NRD
OM icon

Nebula Research & Development’s Outset Medical OM Stock Holding History

Nebula Research & Development’s Portfolio OM Stock Details OM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q3 		– Sell
-1,627
Closed -$534K – 618
2023
Q2 		$534K Buy
+1,627
New +$496K 0.4% 121

Other funds holding OM

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return
BG
Bellevue Group Kuesnacht, Switzerland $4.2B AUM 54.85% 1-Year Est. Return
B
Braidwell Stamford, Connecticut $3B AUM 46.72% 1-Year Est. Return
CIP
Champlain Investment Partners Burlington, Vermont $7.88B AUM 6.82% 1-Year Est. Return
Ameriprise
Ameriprise Minneapolis, Minnesota $432B AUM 30.22% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Nebula Research & Development's OM Position: Q3 2023 in Review

Nebula Research & Development sold out of Outset Medical (OM) in Q3 2023, closing a stake of 1,627 shares — an estimated $534K sold.

Nebula Research & Development first reported a position in OM in Q2 2023 and held it in 1 quarter. The position peaked at $534K in Q2 2023. 152 funds tracked by Wall St. Rank hold OM as of Q3 2023.

  • Nebula Research & Development reported no remaining Outset Medical position as of Q3 2023 after selling out during the quarter.
  • Nebula Research & Development sold 1,627 Outset Medical shares in Q3 2023, an estimated $534K.
  • Nebula Research & Development first reported a position in Outset Medical in Q2 2023 and held it in 1 quarter.
  • Nebula Research & Development's Outset Medical position peaked at $534K in Q2 2023.
  • 152 funds tracked by Wall St. Rank held Outset Medical as of Q3 2023.

Based on Nebula Research & Development's 13F filing for Q3 2023, filed 14 Nov 2023.